FDA Doxazosin Recall: Distributor Action Required

FDA Recall: 60,000 Doxazosin (Cardura) Tablets Nationwide — Distributor Action Required

The FDA issued a Class II recall for 60,000 tablets of doxazosin mesylate 4mg on January 15, 2025, due to failed dissolution specifications. Wholesale drug distributors holding this lot must immediately quarantine inventory, notify downstream customers, and document all distribution records under 21 CFR Part 7 recall procedures.

Regulatory Context

Under 21 CFR 7.45, firms responsible for recalled products must develop recall strategies including depth of recall, public warning methods, and effectiveness checks. For wholesale drug distributors, this triggers obligations under 21 CFR 205.50(g): maintaining records of all transactions involving prescription drugs, including disposition of recalled products. State boards of pharmacy in all 51 jurisdictions require licensed distributors to cooperate with manufacturer-initiated recalls and maintain documentation for inspection.

The Drug Quality and Security Act (DQSA) Title II establishes that wholesale distributors must have systems to facilitate recalls and notify direct purchasers within 24 hours of receiving manufacturer notification. This recall tests those systems across the national distribution network.

Recall Specifications

Product: Doxazosin Mesylate Tablets USP, 4mg

NDC: 72205-054-60

Lot Number: DM240815A

Quantity Recalled: 60,000 tablets (1,000 bottles, 60 tablets per bottle)

Manufacturer: Zydus Pharmaceuticals (USA) Inc.

Reason: Failed dissolution testing — tablets do not release active ingredient at specified rate

Classification: Class II (may cause temporary or medically reversible adverse health consequences; remote probability of serious harm)

Distribution: Nationwide through wholesale channels

Recall Initiation Date: January 15, 2025

FDA Announcement: January 22, 2025

Doxazosin is prescribed for hypertension and benign prostatic hyperplasia (BPH). Failed dissolution means the drug may not deliver therapeutic effect, potentially resulting in uncontrolled blood pressure or worsening BPH symptoms. The Class II designation indicates FDA assessed the risk as moderate but significant enough to require removal from distribution.

Distributor Action Requirements

Wholesale drug distributors who received, stored, or redistributed Lot DM240815A must:

1. Quarantine immediately — Segregate all units of the affected lot in a designated area. Apply "RECALL — DO NOT DISTRIBUTE" labels. Document quarantine action with date, time, responsible person, and quantity.

1. Check distribution records — Under 21 CFR 205.50(a)(5), distributors must maintain complete pedigree data showing all prior transactions. Pull records for this NDC/lot to identify all customers who received product.

1. Notify downstream customers within 24 hours — Contact all direct purchasers (pharmacies, hospitals, clinics) via phone and written notice. Provide lot number, NDC, recall classification, and instructions for returns. Document all customer notifications.

1. Conduct effectiveness checks — Contact customers who do not respond within 48 hours. Verify product has been removed from active inventory. FDA expects 100% account-for status on Class II recalls.

1. Return or destroy product — Follow manufacturer's return instructions. If authorized to destroy on-site, maintain witnessed destruction records with photographic evidence, date, witness signatures, and quantity destroyed.

1. Report to state boards — 17 states require distributors to file recall reports with the state board of pharmacy within 72 hours. Check jurisdiction-specific requirements.

Operational Impact

This recall affects inventory valuation, customer service workload, and warehouse operations. Distributors must divert personnel to records research, customer outreach, and return processing. For entities holding significant doxazosin inventory, financial impact includes product write-offs and potential customer chargebacks for pharmacies that dispensed recalled product before notification.

Compliance scores in ColdChainCheck reflect whether distributors have systems to execute these recalls efficiently. Entities with documented recall procedures, 24-hour customer notification protocols, and complete transaction records demonstrate operational readiness for regulatory actions like this one.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors tracked in ColdChainCheck's directory, 1,234 hold active FDA registration — a prerequisite for legal distribution of prescription drugs like doxazosin. However, only 73 entities in the database have documented recall history, meaning the majority of distributors have not demonstrated recall execution capability in publicly available FDA records.

The average compliance score of 51/100 reflects moderate verification across state licensure, NABP accreditation, and FDA registration. For this recall, the critical compliance signal is not the score itself but whether a distributor maintains the transaction records required under 21 CFR 205.50 to trace lot-specific distribution. ColdChainCheck does not score record-keeping practices directly — those are verified during state board inspections — but entities with higher scores (Good tier: 60-79 points) typically demonstrate broader regulatory compliance infrastructure.

Score Distribution Context:

• 28 entities (2.2%) in Excellent tier (80-100 pts)
• 281 entities (22.0%) in Good tier (60-79 pts)
• 919 entities (72.1%) in Fair tier (40-59 pts)
• 38 entities (3.0%) in Poor tier (20-39 pts)
• 9 entities (0.7%) in Minimal tier (0-19 pts)

The concentration in the Fair tier suggests most distributors have basic licensure and registration but limited additional compliance signals. Recall execution depends on operational readiness — transaction record completeness, customer notification systems, quarantine procedures — which ColdChainCheck cannot measure from public data alone.

For QA Managers and Compliance Officers

• Audit your trading partners — If you source from wholesale distributors, check whether they have verifiable FDA registration. Use the ColdChainCheck directory to confirm active registration status before placing orders. Entities without FDA registration cannot legally distribute recalled product and should not be in your supply chain.

• Document due diligence — When qualifying new distributors, confirm they maintain pedigree records as required under 21 CFR 205.50. Ask for their recall SOP during vendor audits. ColdChainCheck's compliance scores provide a starting point, but operational procedures must be verified directly.

• Monitor recall history — 73 entities in ColdChainCheck have FDA recalls on record. This does not indicate poor compliance — recalls affect even well-managed distributors — but it signals that the entity has executed recall procedures under FDA oversight. Review recall data to assess whether your partners have demonstrated recall capability.

• Cross-reference NABP accreditation — Only 63 entities hold NABP Verified-Accredited Wholesale Distributors (VAWD) accreditation, which includes recall preparedness in its audit criteria. NABP-accredited distributors have third-party verification of recall systems. Check entity profiles for accreditation status.

ColdChainCheck tracks FDA enforcement actions, recalls, and warning letters as part of entity compliance profiles. For ongoing monitoring of distributor compliance signals, refer to the Regulatory Guides section for updates on DSCSA enforcement, recall procedures, and state board actions.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Verify all recall details and regulatory obligations with the FDA, manufacturer recall notices, and your legal counsel before taking action.